CD274 and neoplasm: discussed biomarkers for lung cancer immunotherapy, including PD-L1 expression, tumor infiltrating lymphocytes (TILs), and tumor mutation burden (TMB), which can be used to select patients for immune checkpoint inhibitor (ICB) treatment.